Neumora Therapeutics
NMRA1.6401.86% ( +0.030 )
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Neumora Therapeutics(NMRA) predict that the EBIT is -52.86 M (+25.48%), Miss estimate;the EPS is -0.3 (+28.57%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.05B25.48%
-0.05B27.34%
-0.00B1.86%
EPSExceed expectations
-0.328.57%
-0.3126.19%
+0.01002.38%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf